Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50


Beyond NEOD001 for systemic light-chain amyloidosis.

Varga C, Lentzsch S, Comenzo RL.

Blood. 2018 Sep 21. pii: blood-2018-07-865857. doi: 10.1182/blood-2018-07-865857. [Epub ahead of print] No abstract available.


Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Jul 25. pii: S2152-2650(18)30567-6. doi: 10.1016/j.clml.2018.07.292. [Epub ahead of print]


High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.

Varga C, Comenzo RL.

Bone Marrow Transplant. 2018 Aug 8. doi: 10.1038/s41409-018-0284-4. [Epub ahead of print]


Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.

Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V.

Amyloid. 2018 Jul 21:1-4. doi: 10.1080/13506129.2018.1490261. [Epub ahead of print]


Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center.

Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):759-766. doi: 10.1016/j.clml.2017.06.004. Epub 2017 Jun 17.


A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.


Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C.

Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438. Review.


Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.

Weiss BM, Wong SW, Comenzo RL.

Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23. Review.


First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.


Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G.

Adv Ther. 2015 Oct;32(10):920-8. doi: 10.1007/s12325-015-0250-0. Epub 2015 Oct 23.


Out, Out--Making Amyloid's Candle Briefer.

Comenzo RL.

N Engl J Med. 2015 Sep 17;373(12):1167-9. doi: 10.1056/NEJMe1508746. No abstract available.


Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.


How we treat systemic light-chain amyloidosis.

Chaulagain CP, Comenzo RL.

Clin Adv Hematol Oncol. 2015 May;13(5):315-24. Review.


Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters.

Urbano-Moral JA, Gangadharamurthy D, Comenzo RL, Pandian NG, Patel AR.

Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):657-64. doi: 10.1016/j.rec.2015.01.009. Epub 2015 Jun 17.


Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.


Plasma cell neoplasms, their precursor States, and their prediction of organ damage.

Comenzo RL.

J Clin Oncol. 2014 Sep 1;32(25):2679-82. doi: 10.1200/JCO.2014.56.2892. Epub 2014 Jul 14. No abstract available.


Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP.

Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.


One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress.

Zhou P, Ma X, Iyer L, Chaulagain C, Comenzo RL.

Blood. 2014 May 29;123(22):3440-51. doi: 10.1182/blood-2013-10-535187. Epub 2014 Apr 10.


LECT2 makes the amyloid list.

Comenzo RL.

Blood. 2014 Mar 6;123(10):1436-7. doi: 10.1182/blood-2014-01-549758.


Immunoglobulin light chain amyloidosis.

Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA.

Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. Review.


Supplemental Content

Loading ...
Support Center